StockData
Zymeworks Inc. logo

Zymeworks Inc. (ZYME) stock

ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30141% above fair value
$26.47−2.60 (-8.94%)

Close on Nov 12, 2026Market cap $1.88BP/E 50.9Yield –

Earnings

Zymeworks's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 1, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$256.50M
+829.3% on a year earlier
Adjusted EPS, Q3 FY2026
$2.28
-$0.26 a year earlier
Latest guidance
Issued
Nov 9, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Zymeworks's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Mar 1, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 9, 2026after the close$256.50M+829.3%$2.28–Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026after the close$4.60M-90.6%-$0.62–Release
Q1 FY2026ended Mar 31, 2026May 7, 2026after the close$2.40M-91.1%––Release
Q4 FY2025ended Dec 31, 2025Mar 2, 2026before the open$2.50M-91.9%-$0.55–Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025after the close$27.60M+72.5%-$0.26–Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025after the close$48.70M+153.1%$0.03–Release
Q1 FY2025ended Mar 31, 2025May 8, 2025after the close$27.10M+171.0%-$0.30–Release
Q4 FY2024ended Dec 31, 2024Mar 5, 2025after the close$31.03M+83.3%-$0.31–Release
Q3 FY2024ended Sep 30, 2024Oct 31, 2024after the close$16.00M-3.1%-$0.39–Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024after the close$19.24M+174.8%-$0.49–Release
Q1 FY2024ended Mar 31, 2024May 2, 2024after the close$10.00M-71.9%-$0.42–Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Zymeworks's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
total revenueFY2026$337.00M – $351.00M–NewNov 9, 2026
adjusted EBITDAnon-GAAPFY2026$176.00M – $190.00M–NewNov 9, 2026
adjusted gross operating expenses (non-GAAP)non-GAAPFY2026-20%–NewMay 7, 2026
adjusted gross operating expenses (non-GAAP)non-GAAPFY2026-20%–NewMar 2, 2026
adjusted gross operating expenditures (non-GAAP)non-GAAPFY2028$300.00M–NewMar 2, 2026
aggregate adjusted gross operating expenditures (non-GAAP)non-GAAPFY2028$300.00M–NewMay 7, 2026

Guidance history

Every forecast Zymeworks put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 9, 2026adjusted EBITDAFY2026$176.00M – $190.00MNew
Nov 9, 2026total revenueFY2026$337.00M – $351.00MNew
May 7, 2026adjusted gross operating expenses (non-GAAP)FY2026-20%New
May 7, 2026aggregate adjusted gross operating expenditures (non-GAAP)FY2028$300.00MNew
Mar 2, 2026adjusted gross operating expenses (non-GAAP)FY2026-20%New
Mar 2, 2026adjusted gross operating expenditures (non-GAAP)FY2028$300.00MNew
Aug 10, 2023planned capital expendituresFY2023$10.00MLowered
Aug 10, 2023non-GAAP net operating cash burnFY2023$110.00M – $130.00MNew
May 8, 2023planned capital expendituresFY2023$15.00MReaffirmed
May 8, 2023net operating cash burnFY2023$90.00M – $120.00MReaffirmed
Mar 7, 2023planned capital expendituresFY2023$15.00MNew
Mar 7, 2023net operating cash burnFY2023$90.00M – $120.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Zymeworks filed with the SEC as exhibits to Form 8-K or 6-K

  1. Zymeworks Provides Corporate Update and
    Results
  2. Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3
    Update
  3. Zymeworks Completes Acquisition of Theravance Biopharma
    Update
  4. U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
    Update
  5. Zymeworks Provides Corporate Update and
    Results
  6. Zymeworks to Acquire Theravance Biopharma, Inc.
    Update
  7. to Acquire Theravance Biopharma June 29, 2026 Transaction delivers high-visibility, long-duration recurring cash flows Exhibit 99.2
    Update
  8. Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
    Update
  9. Zymeworks Provides Corporate Update and
    Results
  10. Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
    Update
  11. Zymeworks Provides Corporate Update and
    Results
  12. Zymeworks Outlines Strategic Priorities and Outlook for 2026
    Results
  13. Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
    Results
  14. Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by
    Update
  15. Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
    Update

See a number that looks wrong?